Amneal Receives U.S. FDA Approval for Risperidone Extended-Release Injectable Suspension
(NASDAQ:AMRX) BRIDGEWATER, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced the U.S. Food and Drug Administration (FDA) approval o...
What upside or downside risk does the Q4 2025 product launch present for AMRX’s stock price given potential competition and supply constraints?
How much market share can Amneal realistically capture from Janssen’s Risperdal Consta in the next 12‑18 months?
What is the expected revenue uplift from the 180‑day CGT exclusivity period and how will it affect AMRX’s valuation?
6 days ago